Cigna modified MM 0313 covering vascular lesion treatment, effective September 26, 2025. Here's what billing teams need to know about CPT 17106, 17107, 17108, and HCPCS J8499.
Cigna Healthcare updated its coverage policy for cutaneous and deep tissue hemangioma, port wine stain, and other vascular lesions under policy code MM 0313 in the Cigna system. This modification affects laser destruction procedures billed under CPT 17106, 17107, and 17108, along with oral drug claims submitted under HCPCS J8499. If your practice treats vascular birthmarks, hemangiomas, or vascular malformations and bills Cigna, this change is live as of September 26, 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Treatment of Cutaneous and/or Deep Tissue Hemangioma, Port Wine Stain and Other Vascular Lesions |
| Policy Code | MM 0313 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium |
| Specialties Affected | Dermatology, plastic surgery, pediatrics, vascular surgery, interventional dermatology |
| Key Action | Audit all active Cigna claims for CPT 17106–17108 and J8499 against updated medical necessity criteria before submitting new claims |
Cigna Vascular Lesion Coverage Criteria and Medical Necessity Requirements 2025
The Cigna vascular lesion coverage policy under MM 0313 covers laser destruction of cutaneous vascular proliferative lesions — hemangiomas and other vascular malformations — when medical necessity criteria are met. That phrase "when criteria are met" is doing a lot of work here. It tells you the coverage isn't automatic. Your documentation needs to show why laser treatment was necessary for this patient, not just that a lesion was present.
CPT 17106, 17107, and 17108 are all grouped under the same medical necessity framework. The codes separate by lesion size: 17106 covers less than 10 sq cm, 17107 covers 10.0 to 50.0 sq cm, and 17108 covers over 50.0 sq cm. Get the size documentation right in the operative note. A size error is one of the fastest ways to get a claim denial on these codes.
HCPCS J8499 — prescription drug, oral, nonchemotherapeutic, NOS — also falls under this policy for hemangiomas and other vascular malformations. This is typically the catch-all code used for oral propranolol or similar agents prescribed for infantile hemangioma. Cigna's inclusion of J8499 here signals they're tying oral drug coverage for these conditions to the same medical necessity standard as the laser procedures.
Prior authorization requirements for these procedures vary by plan. Don't assume a standard commercial Cigna plan mirrors a Cigna managed care or Cigna Connect plan. Check the specific plan before scheduling. A missing prior auth on a vascular lesion laser case will cost you more time than it saves in scheduling efficiency.
Cigna Vascular Lesion Exclusions and Non-Covered Indications
The policy data groups CPT 17106, 17107, and 17108 under the label "hemangiomas and other vascular malformations is Considered M." That "Considered M" designation matters. In Cigna's system, "M" typically indicates the procedure is medically necessary — but only when documented selection criteria are met. The implication is clear: bill outside those criteria, and you're looking at a denial.
The real exclusion risk here is cosmetic intent. Vascular lesion treatment on Cigna plans gets scrutinized when the clinical record doesn't make a clear medical case. A port wine stain causing functional impairment, bleeding, or psychological distress with documented clinical impact gets a different review than a note that reads "patient requests treatment of facial birthmark." Your documentation needs to make the medical argument, not leave it to the reviewer to infer.
Cigna's coverage policy does not automatically cover these procedures for purely cosmetic indications. If the lesion isn't causing a clinically significant problem — obstruction, ulceration, bleeding, pain, or documented functional limitation — expect pushback. Build the case in the chart before the claim goes out.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Laser destruction of cutaneous vascular lesions, less than 10 sq cm | Covered when medical necessity criteria met | CPT 17106 | Document lesion size precisely in operative report |
| Laser destruction of cutaneous vascular lesions, 10.0–50.0 sq cm | Covered when medical necessity criteria met | CPT 17107 | Document lesion size precisely in operative report |
| Laser destruction of cutaneous vascular lesions, over 50.0 sq cm | Covered when medical necessity criteria met | CPT 17108 | Document lesion size precisely in operative report |
| Oral non-chemotherapeutic drug for hemangioma or vascular malformation | Covered when medical necessity criteria met | HCPCS J8499 | Typically used for oral propranolol; medical necessity documentation required |
| Purely cosmetic vascular lesion treatment | Not covered | CPT 17106, 17107, 17108 | No functional or clinical impairment documented |
Cigna Vascular Lesion Billing Guidelines and Action Items 2025
The effective date is September 26, 2025. If you're reading this after that date, these requirements are already in effect. Here's what your billing team needs to do now.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for CPT 17106, 17107, and 17108. Confirm that every claim submitted on or after September 26, 2025 documents lesion size in square centimeters in the operative or procedure note. Size determines which code you bill. A missing measurement is an easy reason for Cigna to downcode or deny. |
| 2 | Review all J8499 claims tied to vascular lesion diagnoses. HCPCS J8499 is a non-specific drug code. Cigna will look for a clear link between the oral drug, the diagnosis, and the medical necessity documentation. If your clinic bills J8499 for oral propranolol for infantile hemangioma, make sure the diagnosis code on the claim maps directly to the condition being treated. |
| 3 | Verify prior authorization requirements before scheduling. Check the specific Cigna plan — not just "Cigna" as a blanket category. Prior authorization requirements for vascular lesion billing vary by product line. Call or use Cigna's provider portal to confirm before the patient's procedure date. A retroactive auth request after a denial costs more than the call upfront. |
| 4 | Update your documentation templates for medical necessity. Generic templates that list a diagnosis and a procedure code are not enough. Your clinical notes should explain why the lesion required treatment — functional impairment, ulceration, bleeding, documented pain, or other clinical factors. Cosmetic intent, even if unstated, becomes the default read when the clinical justification isn't explicit. |
| 5 | Flag this policy for your compliance officer if your practice treats a high volume of pediatric hemangioma cases. The J8499 inclusion is the part of this policy most likely to generate unexpected denials. Oral drugs billed under a catch-all HCPCS code, tied to a vascular lesion policy — that's a combination that needs a second set of eyes. If you're not sure how this applies to your payer mix, talk to your compliance officer or billing consultant before the next billing cycle. |
| 6 | Cross-reference your ICD-10 diagnosis codes against Cigna's covered diagnoses. The policy covers hemangiomas and vascular malformations. Make sure your ICD-10 selection is specific. Unspecified vascular lesion codes leave room for denial. Use the most specific diagnosis code the documentation supports. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Vascular Lesion Treatment Under MM 0313
Covered CPT Codes (When Medical Necessity Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 17106 | CPT | Destruction of cutaneous vascular proliferative lesions (eg, laser technique); less than 10 sq cm |
| 17107 | CPT | Destruction of cutaneous vascular proliferative lesions (eg, laser technique); 10.0 to 50.0 sq cm |
| 17108 | CPT | Destruction of cutaneous vascular proliferative lesions (eg, laser technique); over 50.0 sq cm |
Covered HCPCS Codes (When Medical Necessity Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J8499 | HCPCS | Prescription drug, oral, nonchemotherapeutic, NOS |
No ICD-10-CM codes are listed in the MM 0313 policy data. Assign the most specific diagnosis codes your documentation supports — hemangioma, port wine stain, or vascular malformation — from the ICD-10-CM index.
A note on vascular lesion billing reimbursement: Cigna's fee schedule for CPT 17106–17108 varies by region and plan type. Don't assume your contracted rate is the same across all Cigna products in your area. Pull your EOBs from the last 90 days and confirm what each plan type is actually paying. If you see inconsistency, that's a signal to check your contract terms — not just the policy.
Get the Full Picture for CPT 17106
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.